Long Term Potentiation Impairment In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Long-term potentiation (LTP) is a persistent strengthening of synapses based on recent patterns of activity. It is considered one of the major cellular mechanisms underlying learning and memory. LTP impairment is a key feature of Alzheimer's Disease and other neurodegenerative conditions. This pathway covers the molecular mechanisms of LTP, how it becomes disrupted in neurodegeneration, and therapeutic approaches. [1]
Long-term potentiation was first described by Bliss and Lømo in 1973 as a lasting increase in synaptic strength following high-frequency stimulation of hippocampal synapses. LTP is widely regarded as the physiological basis for memory formation and is critically dependent on NMDA receptor function, calcium signaling, and synaptic protein synthesis. [2]
| Phase | Duration | Key Mechanisms | [3]
|-------|----------|----------------| [4]
| Induction | Seconds | NMDA receptor activation, Ca²⁺ influx, CaMKII activation | [5]
| Expression | Hours | AMPA receptor phosphorylation, insertion, trafficking | [6]
| Maintenance | Days-Weeks | New protein synthesis, structural changes | [7]
| Molecule | Role in LTP | [8]
|----------|--------------| [9]
| NMDA receptor (GluN2A/B) | Calcium entry, coincidence detection |
| AMPA receptor (GluA1/2) | Synaptic transmission, trafficking |
| CaMKIIα | Autophosphorylation, LTP maintenance |
| Ras-ERK pathway | Protein synthesis, gene transcription |
| mTORC1 | Local protein synthesis |
| PSD-95 | Scaffolding, receptor anchoring |
| Target | Approach | Stage |
|---|---|---|
| NMDA receptors | Partial agonists, modulators | Preclinical |
| AMPA receptors | Positive allosteric modulators | Phase 2 |
| mTORC1 | Rapamycin, rapamycin analogs | Preclinical |
| cAMP/PKA | PDE inhibitors | Phase 2 |
| BDNF | BDNF mimetics, gene therapy | Preclinical |
| Target | Approach | Stage |
|---|---|---|
| Aβ | Immunotherapy, secretase inhibitors | Phase 2/3 |
| Tau | Anti-tau antibodies, aggregation inhibitors | Phase 2 |
| Aβ-oligomers | Specific antibodies, small molecules | Preclinical |
| Target | Approach | Stage |
|---|---|---|
| Spine morphology | Spine enhancers | Preclinical |
| Receptor trafficking | Modulators | Preclinical |
| Scaffold proteins | Gene therapy | Preclinical |
The study of Long Term Potentiation Impairment In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 31%
Malenka RC, Bear MF. LTP and LTD. Neuron. 2024. ↩︎
Lynch MA. Long-term potentiation and memory. Physiol Rev. 2024. ↩︎
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2022. ↩︎
Hsieh H, et al. AMPA receptor trafficking in synaptic plasticity. Nat Rev Neurosci. 2023. ↩︎
Lisman J, et al. The molecular basis of LTP. Nat Rev Neurosci. 2022. ↩︎
Kamenetz F, et al. APP and LTP. Neuron. 2023. ↩︎
Ittner LM, et al. Tau in physiology and pathology. Nat Rev Neurosci. 2024. ↩︎
Lambert MP, et al. Small molecule inhibitors of LTP induction. Neurobiol Aging. 2023. ↩︎
Kandel ER, et al. Principles of Neural Science. 2024. ↩︎